Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.

Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J.

J Exp Med. 2006 Apr 17;203(4):995-1006. Epub 2006 Mar 20.

2.

Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.

Landais E, Saulquin X, Scotet E, Trautmann L, Peyrat MA, Yates JL, Kwok WW, Bonneville M, Houssaint E.

Blood. 2004 Feb 15;103(4):1408-16. Epub 2003 Oct 16.

PMID:
14563644
3.

Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.

Adhikary D, Behrends U, Boerschmann H, Pfünder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J.

PLoS One. 2007 Jul 4;2(7):e583. Review.

4.

T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.

Gallot G, Hamidou MA, Clémenceau B, Gaschet J, Tiberghien P, Ferrand C, Vivien R, Barbarot S, Coste-Burel M, Moreau A, Vié H.

Clin Immunol. 2006 Apr;119(1):79-86. Epub 2006 Jan 4.

PMID:
16386957
5.

Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.

Delecluse HJ, Feederle R, Behrends U, Mautner J.

Semin Cancer Biol. 2008 Dec;18(6):409-15. doi: 10.1016/j.semcancer.2008.09.001. Epub 2008 Sep 30. Review.

PMID:
18938248
6.

B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.

Moosmann A, Khan N, Cobbold M, Zentz C, Delecluse HJ, Hollweck G, Hislop AD, Blake NW, Croom-Carter D, Wollenberg B, Moss PA, Zeidler R, Rickinson AB, Hammerschmidt W.

Blood. 2002 Sep 1;100(5):1755-64.

PMID:
12176897
7.

A11 Tetramer-assisted characterization of Rta-specific CD8+ T-cell responses in healthy virus carriers.

Yu HX, Srinivasan N, Ren EE, Chan SH.

Tissue Antigens. 2005 Jun;65(6):539-43.

PMID:
15896201
8.

The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.

Mautner J, Bornkamm GW.

Eur J Cell Biol. 2012 Jan;91(1):31-5. doi: 10.1016/j.ejcb.2011.01.007. Epub 2011 Apr 1. Review.

PMID:
21458882
9.

Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response.

Neuhierl B, Feederle R, Adhikary D, Hub B, Geletneky K, Mautner J, Delecluse HJ.

J Virol. 2009 May;83(9):4616-23. doi: 10.1128/JVI.01613-08. Epub 2009 Feb 25.

10.

A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.

Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, McMichael AJ, Rickinson AB, Callan MF.

J Immunol. 1999 Feb 1;162(3):1827-35.

11.

Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.

Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD, Reinke P.

J Immunother. 2007 Nov-Dec;30(8):817-24.

PMID:
18049333
12.

Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Niller HH, Wolf H, Minarovits J.

Autoimmunity. 2008 May;41(4):298-328. doi: 10.1080/08916930802024772. Review.

PMID:
18432410
13.

Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.

Merlo A, Turrini R, Bobisse S, Zamarchi R, Alaggio R, Dolcetti R, Mautner J, Zanovello P, Amadori A, Rosato A.

J Immunol. 2010 May 15;184(10):5895-902. doi: 10.4049/jimmunol.0902850. Epub 2010 Apr 12.

15.

Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6.

Flamand L, Stefanescu I, Ablashi DV, Menezes J.

J Virol. 1993 Nov;67(11):6768-77.

16.

T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis.

Klein E, Ernberg I, Masucci MG, Szigeti R, Wu YT, Masucci G, Svedmyr E.

Cancer Res. 1981 Nov;41(11 Pt 1):4210-5.

17.

Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.

Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.

Cancer Sci. 2008 Aug;99(8):1633-42. doi: 10.1111/j.1349-7006.2008.00852.x.

18.

Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells.

Al Tabaa Y, Tuaillon E, Bollore K, Foulongne V, Petitjean G, Seigneurin JM, Duperray C, Desgranges C, Vendrell JP.

Blood. 2009 Jan 15;113(3):604-11. doi: 10.1182/blood-2008-02-136903. Epub 2008 Oct 9.

PMID:
18845794
19.

Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers.

Benninger-Döring G, Pepperl S, Deml L, Modrow S, Wolf H, Jilg W.

Virology. 1999 Nov 25;264(2):289-97.

20.

EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.

van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IG, Buisson M, Hartgers FC, Burmeister WP, Wiertz EJ, Ressing ME.

J Immunol. 2011 Feb 1;186(3):1694-702. doi: 10.4049/jimmunol.0903120. Epub 2010 Dec 29.

Supplemental Content

Support Center